Quick Answer
Spero Therapeutics, Inc. reported R&D Expense of $38.47 million for fiscal year 2025.
Spero Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $38.47M | -60.2% |
| 2024 | $96.76M | +88.1% |
| 2023 | $51.44M | +8.1% |
| 2022 | $47.59M | -26.2% |
| 2021 | $64.53M | -3.7% |
| 2020 | $67.00M | +1.9% |
| 2019 | $65.78M | +94.1% |
| 2018 | $33.88M | +3.1% |
| 2017 | $32.87M | +24.8% |
| 2016 | $26.33M | +136.7% |
| 2015 | $11.12M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.60M | -68.0% | -19.4% |
| June 30, 2025 | $10.67M | -55.0% | -21.6% |
| March 31, 2025 | $13.61M | -21.5% | -49.4% |
| September 30, 2024 | $26.86M | +63.9% | +13.2% |
| June 30, 2024 | $23.73M | +149.5% | +36.9% |
| March 31, 2024 | $17.33M | +93.0% | +5.7% |
| September 30, 2023 | $16.39M | +122.7% | +72.4% |
| June 30, 2023 | $9.51M | +16.4% | +5.9% |
- Spero Therapeutics, Inc. showed a decrease of -60.2% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, Spero Therapeutics, Inc.’s r&d expense has grown by 245.8% (from $11.12 million to $38.47 million).
- The most recent figure is from Spero Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: